
Get exclusive money-saving offers and guides
Straight to your inbox
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Genetic Technologies Limited is a diagnostics & research business based in Australia. Genetic Technologies shares (GTG) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Genetic Technologies has a trailing 12-month revenue of around $9,864.
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
52-week range | $0.003 - $0.014 |
---|---|
50-day moving average | $0.0101 |
200-day moving average | $0.0087 |
Target price | $0.25 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.002 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Revenue TTM | $9,864 |
---|---|
Gross profit TTM | $-241,647 |
Return on assets TTM | -48.8% |
Return on equity TTM | -82.49% |
Profit margin | 0% |
Book value | 0.002 |
Market capitalisation | $90.1 million |
TTM: trailing 12 months
We're not expecting Genetic Technologies to pay a dividend over the next 12 months.
Genetic Technologies 's shares were split on 29 December 1994.
Over the last 12 months, Genetic Technologies 's shares have ranged in value from as little as $0.003 up to $0.014. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Genetic Technologies 's is 0.8463. This would suggest that Genetic Technologies 's shares are less volatile than average (for this exchange).
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company engages in the development of various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer name. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.
Steps to owning and managing Liberty Financial Group shares.
Steps to owning and managing Cettire shares.
Steps to owning and managing BHP Group shares.
Steps to owning and managing Fisher & Paykel Healthcare Corp Ltd shares.
Steps to owning and managing MicroStrategy shares.
Everything we know about the Superhero IPO, plus information on how to buy in.
Everything we know about the Coinbase IPO, plus information on how to buy in.
Everything we know about the Databricks IPO, plus information on how to buy in.
Steps to owning and managing Ligand Pharmaceuticals shares.
You can't access Robinhood in Australia, so here are five low-cost alternatives to trade US stocks.